Gland Pharma shares plummeted nearly 20% on Monday, taking its two-day fall to 34%. Watch this Visual Story to see if you should buy the dip in Gland Pharma share price.
The drugmaker reported a 72 per cent YoY drop in net profit to Rs 79 crore in Q4FY23 due to a production shutdown at one of its facilities in Telangana and soft demand.
Kotak said the near-term outlook for Gland Pharma is sluggish but the product pipeline and entry into new markets provide medium-term growth visibility.